KPTI vs KTTA

Karyopharm Therapeutics Inc. vs Pasithea Therapeutics Corp. — Valuation Comparison 2026

KPTI

Pharmaceutical Preparations
Karyopharm Therapeutics Inc.
Quality
5.1
out of 10
Value Trap
30
LOW
Price
$9.10
Last close
Models
7/13
Active
VS

KTTA

Pharmaceutical Preparations
Pasithea Therapeutics Corp.
Quality
4.1
out of 10
Value Trap
24
SAFE
Price
$0.72
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType KPTI Fair ValueKPTI Upside KTTA Fair ValueKTTA Upside
Bayesian DCF Intrinsic $3.13 -65.6% $1.30 +81.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.30 +222.0%
PWERM Option-Based $23.88 +162.4% $0.75 +5.2%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for KPTI vs KTTA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KPTI vs KTTA — Which Stock Is More Undervalued?

KPTI scores higher with a 5.1/10 quality rating vs KTTA's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Karyopharm Therapeutics Inc. (KPTI) and Pasithea Therapeutics Corp. (KTTA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KPTI currently trades at $9.10 with a QOC of 5.1/10, while KTTA trades at $0.72 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).